Using Structure-guided Fragment-Based Drug Discovery to Target *Pseudomonas aeruginosa* Infections in Cystic Fibrosis

Sheikh Mohammed Arif¹, R. Andres Floto²,³ and Tom L. Blundell¹ *

¹Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom, ²Molecular Immunity Unit, Department of Medicine University of Cambridge, MRC-Laboratory of Molecular Biology, Cambridge, United Kingdom, ³Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge, United Kingdom

Cystic fibrosis (CF) is a progressive genetic disease that predisposes lungs and other organs to multiple long-lasting microbial infections. *Pseudomonas aeruginosa* is the most prevalent and deadly pathogen among these microbes. Lung function of CF patients worsens following chronic infections with *P. aeruginosa* and is associated with increased mortality and morbidity. Emergence of multidrug-resistant, extensively drug-resistant and pandrug-resistant strains of *P. aeruginosa* due to intrinsic and adaptive antibiotic resistance mechanisms has failed the current anti-pseudomonal antibiotics. Hence new antibacterials are urgently needed to treat *P. aeruginosa* infections. Structure-guided fragment-based drug discovery (FBDD) is a powerful approach in the field of drug development that has succeeded in delivering six FDA approved drugs over the past 20 years targeting a variety of biological molecules. However, FBDD has not been widely used in the development of anti-pseudomonal molecules. In this review, we first give a brief overview of our structure-guided FBDD pipeline and then give a detailed account of FBDD campaigns to combat *P. aeruginosa* infections by developing small molecules having either bactericidal or anti-virulence properties. We conclude with a brief overview of the FBDD efforts in our lab at the University of Cambridge towards targeting *P. aeruginosa* infections.

**Keywords**: FBDD, fragment-based drug discovery, antibiotics, cystic fibrosis, *Pseudomonas*, anti-virulence

**INTRODUCTION**

Cystic fibrosis (CF) is a life-shortening autosomal-recessive Mendelian disease affecting approximately 100,000 people worldwide (Cystic Fibrosis Foundation, 2017 Annual Data Report, 2021; United Kingdom; Cystic Fibrosis Registry 2020 Annual Data Report, 2021). In the 1950s, the majority of the CF patients did not live beyond infancy (Davis, 2006; Elborn, 2016). Four decades later, the life expectancy had improved to 31 years (Cystic Fibrosis Foundation. 2017. Cystic Fibrosis Foundation patient registry. 2016 annual data report. Cystic Fibrosis Foundation, Bethesda, MD.). At present, with further improvement in the diagnosis and treatment, the median survival age of CF patients has increased to 50.6 years in United Kingdom (UK Cystic Fibrosis Registry 2020 Annual Data Report, 2021) and 59 years in United states (UK Cystic Fibrosis Registry 2020 Annual Data Report, 2021). The majority of morbidity and mortality in CF is caused by chronic bacterial lung infections.
infections (Elborn, 2016; Molina and Hunt, 2017). CF is caused by bi-allelic deletions mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, leading to defects in chloride and bicarbonate ion transport across epithelial surfaces, and consequently the production of thick secretions that disrupt mucociliary clearance in the lungs, predisposing to chronic bacterial infections, and progressive inflammatory lung disease.

The most important bacterial infection in CF is *P. aeruginosa*, a Gram-negative bacterium that, in addition to causing opportunistic and hospital-acquired infections, can cause chronic respiratory infections in individuals with underlying inflammatory lung disease, including CF. Approximately 40% of the adult CF population in the United Kingdom is currently chronically infected with *P. aeruginosa* (2019 CF registry), leading to increased mortality and morbidity (Flume et al., 2007; Crull et al., 2018) associated with the emergence of multi-drug resistant organisms and antibiotic failure.

### Current Treatment Regimens for *P. aeruginosa* Infections and Need for Novel Therapeutics

At present, nine categories of anti-pseudomonal antibiotics are used to treat *P. aeruginosa* infections including penicillin-β-lactamase combinations (pipercillin-tazobactam and ticarcillin-clavulanate), cephalosporins (Cefazidime, Cefepime, Cefoperazone and Cefiderocol), a monobactam (aztreonam), fluoroquinolones (Ciprofloxacin, Levofloxacin, Prulifloxacin, Delafloxacin and Finaflaxacin), a phosphonic acid derivative (Fosfomycin), carbapenems (Doripenem, Imipenem/cilastatin and Meropenem), novel β-lactams with β-lactamase inhibitors (ceftazidine–avibactam, cefotolozane/tazobactam, Imipenem/cilastatin–relebactam, Meropenem–vaborbactam), aminoglycosides (Tobramycin, Gentamicin, Amikacin and Plazomicin) and polymyxins (Colistin and PolymyxinB) (Ibrahim et al., 2020).

*P. aeruginosa* is equipped with a high level of intrinsic antibiotic resistance owing to restricted outer membrane permeability, efflux systems that pump antibiotics out of the cell and production of antibiotic-inactivating enzymes such as β-lactamases. *P. aeruginosa* can also readily acquire antibiotic resistance through mutations and acquisition of resistance plasmids (Potron et al., 2015; Pang et al., 2019), leading to the emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) strains of *P. aeruginosa* (El Zowalaty et al., 2015; Bassetti et al., 2018). In addition, *P. aeruginosa* possesses adaptive resistance mechanisms against antibiotics, including biofilm-mediated resistance and the formation of multidrug-tolerant persister cells which further limit the effectiveness of current antibiotic treatments (Pang et al., 2019). As a consequence this pathogen is listed in the “critical” category of antibiotic-resistant “priority pathogens” published recently by WHO (WHO, 2017) (Shrivastava et al., 2018). Hence, there is an urgent need for new antibiotics along with the discovery and development of novel potential therapeutic strategies such as quorum sensing inhibition, lectin inhibition, iron chelation, phage therapy, vaccine strategy, nanoparticles, antimicrobial peptides and electrochemical scaffolds, which present new avenues against *P. aeruginosa* infections (Pang et al., 2019).

### Fragment-Based Drug Discovery Approach and Work Flow

Structure-guided fragment-based drug discovery (FBDD) is a powerful approach, now widely used both in academia and industries to produce novel high-quality drug-like molecules (Blundell et al., 2002; Murray and Rees, 2009; Scott et al., 2012; Mashalidis et al., 2013; Erlanson et al., 2016). This approach involves screening a library consisting of small “fragments” (MW < 300 Da) of drug-like molecules against a defined target protein, using various biophysical, biochemical and structural biology methods. Compared with the traditional high-throughput screens of drug-sized molecules, the binding and subsequent growth of low molecular weight fragments to drug-like compounds allows a more extensive exploration of chemical space even when using small libraries and can lead to superior molecules. Although fragments are usually weak binders, they can bind to hotspots that allow well-defined interactions with the target protein. These can be entropically favourable due to displacement of previously organised bound water molecules (Radoux et al., 2016). The three-dimensional binding mode of these fragments is explored by determining the structure of the fragment-bound target using X-ray crystallography, NMR spectroscopy or cryoelectron microscopy, and guided by these structures the fragments are chemically “grown” or “linked” to form a larger molecule with higher affinity and drug-like properties. Over the past 20 years, FBDD has achieved significant success by delivering six FDA approved drugs namely, vemurafenib (Bollag et al., 2012), venetoclax (Souers et al., 2013), erdafitinib (Perera et al., 2017), pexidartinib (Tap et al., 2015), sotorasib (Blair, 2021) and Asciminitib (Eşkazan, 2021) (Table 1). In addition, more than 40 molecules discovered by FBDD are currently in active clinical development (Erlanson, 2021). Four of these molecules: capivasertib (AstraZeneca/Astex/CRUK), lanabecestat (AstraZeneca/Lilly), palbociclib (CP-0610) (Constellation) and verubecestat (Merck) have reached in the phase 3 of the clinical trial (Erlanson, 2021). However, the use of FBDD for the development of anti-pseudomonal molecules has been limited to only a handful of studies, some of which will be discussed later in this review, but focusing on the contribution of our own lab.

Until recently one of the main limitations of fragment-based approaches was the need to have crystals with sufficient resolution to see the fragments. This is now less of a problem as many companies such Astex and Astra Zeneca, as well as our own academic work, has been radically transformed by the use of cryo-EM. The power of cryo-EM to visualise small molecules is illustrated by recent work in both our academic work and Astex company work, where cryo-EM is now being widely used for fragment-based drug discovery. A recent example from our academic work is on visualising small drug molecules in the 4,000 amino acid DNA-PKcs published in Nature (Liang et al., 2022).
We now review the steps involved in a typical target-oriented structure-guided fragment based drug discovery (Figure 1).

**Target Selection**

Target selection is the first step in our drug discovery pipeline. A systematic analysis of literature on gene essentiality is performed in order to select essential drug-targets. These studies include various molecular genetic approaches, such as gene trapping, homologous recombination, transposon insertion mutagenesis (Van Opijnen and Camilli, 2013; Chao et al., 2016), and more recently developed CRISPR/CAS9 gene editing system (Wang et al., 2015; Evers et al., 2016; Morgens et al., 2016; Senturk et al., 2017; Bartha et al., 2018; You et al., 2020), to identify essential genes by first incorporating inactivating mutations in them and then determining the viability of the cells or organism carrying these mutations. The next step is to look for the similarity of these essential genes to those of the human genome. Targets similar to a gene in the human genome or human gut microbiome are not pursued in order to avoid cross-reactivity of the developed antibiotic and maintain the health of the microbiome. The protein products of these genes are considered for selecting a target. This is followed by the ligandability/druggability analysis by detecting and evaluating the ligand binding sites using modelling programs, such as the α-shape based approach (Edelsbrunner and Mücke, 1994) in MOE (MOLECULAR OPERATING ENVIRONMENT; 2016 Integrated Computer-Aided Molecular Design Platform), SiteMap (Halgren, 2009), LIGSITE (Huang and Schroeder, 2006), CASTp (Dundas et al., 2006) and more recently by generating fragment HOTSPOT maps (Radoux et al., 2016), taking advantage of the available 3-dimensional structure for potential target proteins. Cryptic binding sites can be detected by molecular dynamics simulations (Kuzmanic et al., 2020) and the cosolvent mapping method (Yang and Wang, 2010). In cases where the 3-dimensional structures are not available, they can be modelled using software such as Modeller (Šali and Blundell, 1993; Eswar et al., 2006) and more recently developed deep-learning algorithms, such as AlphaFold (Senior et al., 2020), AlphaFold2 (Jumper et al., 2021) and RoseTTAFold (Back et al., 2021), and the resulting structure can be then analysed for ligandability. Other criteria while selecting a target include preference for non-membrane proteins and availability of well-established biochemical/functional assays in order to achieve a speedy drug-discovery process.

**Target Protein Production**

Once the target protein is selected, the corresponding gene is cloned into an expression vector using molecular biology
techniques such as PCR (Mullis, 1990; Garibyan and Avashia, 2013; Hoseini and Sauer, 2015) and ligation (Cohen et al., 1973) resulting in an expression plasmid. The target protein is often overexpressed in *Escherichia coli* using this expression plasmid. The overexpressed protein is purified in large quantity using protein chemistry techniques such as affinity chromatography (Rodriguez et al., 2020), ion-exchange chromatography (Walls and Walker, 2017) and size exclusion chromatography (Burgess, 2018; Held and Kilz, 2021).

### Design/Selection of Fragment Library for a Selected Target

Designing/selecting a generic fragment library for a fragment-screening campaign in general involves considerations such as diversity, solubility, molecular weight (MW), cLogP, polar surface area (PSA), Fsp3 (Lovering et al., 2009; Wei et al., 2020), natural product-likeness and the number of the fragments (Mahmood and Ramachandraiah, 2021). On the other hand, there are certain criteria that are important to consider while assembling/choosing a fragment library with high chemical and structural diversity to be used for screening against a selected target. These involve ligand and protein structure-based approaches of library design/selection (Schuffenhauer et al., 2005). The ligand-based approach involves the knowledge of binding mode of known ligands for the target and the fragments that can undergo similar interactions with the target are selected. Importantly, such interactions are often conserved over the whole target family and hence a fragment identified using this approach can be used to target other members of the family. An example of...
such approach include selection of metal chelators in a fragment screening campaign against gelatinase (Wang et al., 2002). Commercial fragment libraries dedicated for matrix metalloprotease (MMPs) such as Chelator Fragment Libraries (CFL 1.1), comprising a range of metal chelating moieties (Agrawal et al., 2008) and protease inhibitor-enriched library (Raell and Holloway, 2010), have been deliberately chosen to target a matrix metalloproteinase, LasB (Garner et al., 2012; Kany et al., 2018a). Another example of target-focussed libraries are halogen-enriched fragment libraries (HEFLibs), comprising chemical probes that identify halogen bonds as the main feature of binding mode, and originally constructed to find chemical moieties that stabilise p53 mutants (Heidrich et al., 2019). Structure-based approaches for design/selection of the fragment library may involve in silico screening as described for DNA gyrase ligands (Boehm et al., 2000). The hit rates in fragment screening with such target-focused fragment libraries are much higher than those with generic fragment libraries.

**Fragment Screening to Identify Hits**

Biophysical, biochemical, structural biology and computational methods are used to screen a library of fragments (~1,000) against the target. The most popular biophysical method used for screening is differential scanning fluorimetry (DSF), often known as thermal shift assay, a technique that measures the denaturation temperature (melting temperature, Tm) of the protein (Senisterra et al., 2012) and allows the detection of compounds that increase the Tm of a target protein on binding by promoting protein stability (Niesen et al., 2007). Surface plasmon resonance (SPR), a label-free technique, is another biophysical technique that is used for direct screening of fragment libraries (Navratilova and Hopkins, 2010). Fragment-screening by SPR is advantageous owing to its cost-effectiveness, the possibility of high-throughput mode and the requirement of a very small amount of protein (Neumann et al., 2007; Chavanie and Pugnière, 2016). NMR spectroscopy can also be used to perform initial screening, possibly using cocktails of fragments to accelerate the procedure (Leach, 2006).

Microscale thermophoresis (MST), another well-established biophysical technique to quantify any kind of biomolecular interaction (Jerabek-Willemsen et al., 2014; Mueller et al., 2017), is based on thermophoretic mobility, the directed motions of biomolecules and macromolecular complexes in solution in a temperature gradient; these strongly depend on molecular properties such as size, charge, hydration shell or conformation. MST enables the identification of compounds whose binding to a target changes the thermophoretic mobility of the target (Asmari et al., 2018), including even the weak binders, such as fragments (Linke et al., 2016). It has been demonstrated that MST is amenable for implementation into high-throughput screening cascades (Rainard et al., 2018) and has potential to maximize the efficacy of fragment screening campaigns owing to a high degree of automation in the technique generating quantitative data for affinity ranking in a rapid and precise manner (Rainard et al., 2018). Biolayer interferometry (BLI), especially useful for targeting protein–protein interactions (Wartchow et al., 2011), and nanoelectrospray ionization mass spectrometry (ES-MS) (Maple et al., 2012) are other methods that have recently been used for fragment screening and ranking.

Crystal-based screening of a fragment library has also been developed (Patel et al., 2014), and this is routinely practiced at the XChem facility of Diamond Light Source, United Kingdom as a highly streamlined process, allowing more than 1,000 fragments to be screened in less than a week (Douangamath et al., 2020, https://www.diamond.ac.uk/Instruments/Mx/Fragment-Screening.html). For this, many crystals of the target protein are produced and the fragments are soaked in these crystals using the acoustic droplet ejection technique (Collins et al., 2017). High-throughput X-ray diffraction data collection (36 h of unattended beamtime) is carried out on the resulting crystals at the dedicated beamline, IO4-1, of the Diamond Light Source. The processing of X-ray data is performed automatically while the data are being collected, using the dedicated data processing software such as xia2 (Winter 2010) among others. The structure solution and map analysis is performed by the XChemExplorer package (Krojer et al., 2017) including modules such as DiffeMap (Difference Map PipeLinE) for initial refinement and automated difference map calculation to allow for quick assessment of X-ray data to see if a ligand has bound to the structure; AceDRG (Long et al., 2017) for generation of ligand restraints; REFMAC (Murshudov et al., 2011) for refinement; PanDDA (Pearce et al., 2017) for the streamline density interpretation and hit detection; a number of tools from PHENIX (Adams et al., 2010) for structure validation; and Coot (Emsley et al., 2010) for automated model building. The advantage of crystal-based screening is that it can detect fragments that have very weak binding affinities to the target protein.

To cut the cost of experiments and as a pre-screen, virtual docking of the fragment library on the three-dimensional structure of target protein, known as virtual screening (VS), is often performed in order to obtain initial hits (Bieliska et al., 2011; Singh et al., 2018; Yamaotsu and Hirono, 2018; Gimeno et al., 2019). However, it is of note that these hits are hypothetical and warrant experimental validation (Zhu et al., 2013). VS is advantageous in cases where a very large library comprising millions of scaffolds has to be screened, where it can reduce the number of molecules needed to be screened experimentally by other biophysical/biochemical methods. VS campaign can be supplemented by machine and deep learning principles, especially when dealing with large data sets (Melville et al., 2009). Machine learning approaches in ligand-based VS can address complex compound classification problems and help predict new active molecules (Lavecchia, 2015). Deep learning in the field has emerged in recent years and it has been demonstrated to have utility beyond bioactivity prediction to other drug discovery problems such as de novo molecular design, synthesis prediction and biological image analysis (Chen et al., 2018).

**Hit Validation**

Hits from initial screening are confirmed by ligand-based NMR spectroscopy (Hajduk et al., 1997; Mayer and Meyer, 1999; Dalvit et al., 2001). Real-time fragment-binding affinity and kinetics can be determined using SPR (Yadav et al., 2012; Capelli et al., 2020) and thermodynamics of fragment binding is determined using...
isothermal titration calorimetry (ITC) (Srivastava and Yadav, 2019). The 3D structures of protein-fragment complexes are determined using X-ray crystallography to instruct the process of fragment elaboration. Functional biochemical assays are performed to measure the inhibition activity of the fragments.

Fragment to Lead Optimization and Cell-Based Assays
Guided by the 3D structure of protein-fragment complexes the fragments are elaborated using growing (Hoffer et al., 2018), merging (Nikiforov et al., 2016; Miyake et al., 2019) or linking (Bancet et al., 2020), whichever suits in order to generate compounds with higher affinity and drug-like properties. In-silico molecular modelling is a remarkably beneficial tool as, together with X-ray and cryo-electron microscopy, it provides a means to develop a suitable linker to attach to the low-affinity molecules (Scoffin and Slater, 2015; de Souza Neto et al., 2020). We do this with the help of our chemistry collaborators. The elaborated compounds are then tested by ITC for their affinities to target and functional assays for their inhibition activity against the target. An iterative cycle of fragment growing/merging/linking, followed by biophysical, biochemical and structural analyses while maintaining high ligand efficiency is established. The final compounds, often achieving nanomolar affinities and having potent in vitro inhibition, are then used for cell-based assays to check their minimal inhibitory concentrations (MICs) (Kowalska-Krochmal and Dudek-Wicher, 2021). We do this with the help of our cell biologist collaborators.

Expected Outcomes
Small “fragments” of drug-like molecules may bind to hotspots on a defined protein target. The initial screening of a library of fragments (~1,000) often results in several fragments (~20–50) binding to a target. Hit validation should lead to 5–10 fragments having significant affinity to the target. Fragments can be chemically “grown” or “linked” to deliver compounds with nanomolar binding affinities to the target and altering its activity. Such small-molecule inhibitors developed against essential protein targets can be developed into lead compounds. Further chemical modification of the chemical structure of the lead compound can lead to improvement in potency, selectivity and pharmacokinetic parameters. The pharmacologically active moiety thus obtained may have poor drug likeness which can usually be further modified chemically to result in a more drug-like compound for testing biologically or clinically. Such a compound should be able to compromise the growth and survival of the pathogen inside the host organism.

### ANTIBIOTIC STRATEGIES TARGETING P. AERUGINOSA

**Targeting Lipopolysaccharide Biosynthesis Pathway**

**Fragment-Based Drug Discovery on LpxA and LpxD**
The presence of an outer membrane in Gram-negative bacteria (GNB) protects the bacterial cell not only from the harsh environment but also antibiotics (Koch, 2017). Lipopolysaccharide (LPS), the major component of the outer leaflet of this membrane (Raetz and Whitfield, 2002), are virulence factors essential in many clinically important GNBs, such as *P. aeruginosa*, where it plays important roles in the structural integrity of the bacteria and its defence against the host; hence the enzymes of the LPS biosynthesis pathway are attractive drug targets (Cryz et al., 1984; King et al., 2009). Although there are currently no antibiotics targeting LPS biosynthesis, compounds inhibiting this biochemical pathway can lead to the development of new antibiotics with novel mechanism of action (Jackman et al., 2000; Joo, 2015). Lipid A, a glucosamine disaccharide that is connected to multiple fatty acid chains of various lengths, is the minimal component of LPS required for cellular viability in most GNBs (Anderson et al., 1993; Rotella, 1997; Raetz and Whitfield, 2002). Moreover, lipid A is the antigenic determinant of LPS that triggers septic shock. The enzymes of the LPS biosynthesis pathway, including lipid A biosynthesis, are attractive drug targets for therapeutic interventions. An *in silico* study suggests that, in *P. aeruginosa*, a total of thirteen enzymes are involved in this LPS biosynthesis, of which seven enzymes matched with the list of candidate essential genes obtained by transposon mutagenesis study (Perumal et al., 2007). These enzymes have no human homologues and hence they can serve as potential drug targets.

LpxA, LpxC and LpxD are the first three enzymes in lipid. A biosynthesis pathway. Of these, LpxC has been extensively targeted by antibiotic discovery leading to the development of many small molecule inhibitors with antibacterial properties (Kalinin and Holl, 2017). In contrast, LpxA and LpxD have remained largely unexplored for the development of small

| Compound | Structure | LpxA (µM) | LpxD (µM) |
|----------|-----------|-----------|-----------|
| 1        | ![Structure](image1.png) | NA        | NA        |
| 2        | ![Structure](image2.png) | 19.5      | 36.7      |
| 3        | ![Structure](image3.png) | 16.7      | NB        |
| 4        | ![Structure](image4.png) | 13.6      | NB        |
| 5        | ![Structure](image5.png) | 2.1       | NB        |

*TABLE 2* Binding affinities to *P.* *LpxA* and *P.* *LpxD* of the novel small-molecule scaffolds identified following an FBDD campaign. A few of them show dual binding having affinities to both *P.* *LpxA* and *P.* *LpxD*. NA: binding affinity could not be determined; NB: No binding.
molecule inhibitors and are targeted mostly by antibacterial peptides (Williams et al., 2006; Jenkins and Dotson, 2012; Jenkins et al., 2014; Dangkulwanich et al., 2019). LpxA and LpxD are amenable to dual-targeting inhibitors due to their structural similarity and the advantage of such inhibitors include increased potency and reduced likelihood of resistance against the inhibitors (Silver, 2007). FBDD against LpxA and LpxD to develop dual-targeting inhibitor was performed by Kyle G. Kroeck and co-workers (126). An initial fragment screening by virtual docking of a subset of the ZINC fragment library of John J. Irwin and Brian K. Shoichet (Irwin and Shoichet, 2005), followed by SPR characterization of binding fragments and X-ray crystallography analysis of enzyme-fragment complexes to verify binding and to reveal binding modes for lead optimization have identified novel small-molecule scaffolds that can serve as starting point for future inhibitor discovery (Kroeck et al., 2019). Several of these novel ligands, which have shown dual-binding activity (Table 2), have the potential to result in small molecule inhibitors targeting LpxA and LpxD simultaneously. For instance compound 1 in its complex with LpxA and LpxD adopted similar binding poses in the two acyl-chain binding pockets revealing both the structural similarities and differences that can guide the development of future dual-targeting inhibitors. Interestingly, these structures also highlight additional binding hot spots shared by the two enzymes that can be exploited for further lead optimization.

### Fragment-Based Drug Discovery on LpxC

The bacterial enzyme UDP-3-O-acyl-N-acetylglicosamine deacetylase (LpxC) is an attractive target for the development of novel therapeutic agents (Erwin, 2016; Chen et al., 2019). It is essential to most Gram-negative bacteria including *P. aeruginosa* (Raetz and Whitfield, 2002, 2002) and catalyzes the removal of an N-acetyl group from UDP-3-O-acyl-N-acetylglicosamine (which constitutes the core of Lipid A), the first committed step in biosynthesis of the LPS, which is an essential component of the bacterial cell wall. Several series of inhibitors have been developed against *P. aeruginosa* LpxC (PaLpxC) employing non-FBDD approach (Erwin, 2016; Kalinin and Holl, 2017; Chen et al., 2019) exploiting the following features of molecules at the binding site: 1) a zinc-chelating motif, 2) a polar group occupying the UDP binding pocket, 3) a linker that is mainly hydrophobic but sometimes makes at least one hydrogen bond interaction, 4) an extended hydrophobic moiety that binds in the tunnel, and 5) often addition of groups out into the solvent at the end of the tunnel to modulate compound properties. The most advanced compounds carry a hydroxamate moiety that coordinates the zinc ion at the core of the enzyme. One of these compounds, ACHN-975 (Cohen et al., 2019; Lpxc et al., 2019), a hydroxamate-based histone deacetylase inhibitor (HDACI) entered clinical trial and was approved by FDA for its use in oncology applications but was discontinued beyond oncology (Lpxc et al., 2019) due to its off-target side effects associated with hydroxamate group (Shen and Kozikowski, 2016).

Therefore, an FBDD campaign, to identify LpxC inhibitors with a non-hydroxamate metal-coordinating group, was started (Yamada et al., 2020). 1,152 compounds from the Vernalis Research fragment library (Baurin et al., 2004; Chen and Hubbard, 2009) were screened against PaLpxC by ligand-observed NMR (STD, water-LOGSY, and CPMG), using cocktails of 6 fragments (Hubbard et al., 2007; Hubbard and Murray, 2011) followed by singleton NMR competition assays to look for the competitive binding of

---

**FIGURE 2**  (A) Location of compound 11 [2-(1S-hydroxyethyl)-imidazole] in the PaLpxC-11 complex structure (pdb id 7ci9) determined by X-ray crystallography (Yamada et al., 2020). The protein binding site is represented as grey surface and the compound as stick. The zinc ion is shown as an orange sphere. (B) Structure-guided elaboration of fragments 8 and 9, leading to compounds 10 and 11, respectively with enhanced potencies and inhibition properties.
the fragments with respect to binding of the tool compounds 6 and 7, (hydroxamate group containing inhibitors reported previously) to LpxC. The 28 fragments showing competitive binding were further assessed in the Fluorescence Polarization (FP) binding assay followed by Fluorescamine-Based Functional Activity Assay. Some of which such as 8 showed clear inhibition with an IC$_{50}$ of 41.9 μM. Two zinc-chelating fragments, a glycine fragment 8 and an imidazole fragment 9, both of which were competitive with 6, were selected for further investigation. Both of these were shown to stabilize LpxC in a TSA experiment further confirming the binding. The crystal structure of PaLpxC-fragment 8 complex guided the initial medicinal chemistry and iterative cycle of protein-ligand co-crystallization, confirming binding poses, structure-based modeling predicting the binding poses and guiding the possibility of enhancing potency and chemical modification. This led to the development of a compound 10 with many fold increase in the activity (functional IC$_{50}$ 0.00603 μM) as compared to initial fragment 8 (functional IC$_{50}$ 41.9 μM). However, this compound showed only weak antibacterial activity even in the presence of phenylalanine-arginine β-naphthylamide (PAβN) (an efflux pump inhibitor) (MIC of 8 μg/ml against P. aeruginosa and 64 μg/ml against P. aeruginosa ATCC27853), so this series was not pursued any further. Similar medicinal chemistry on imidazole fragment 9 resulted in an advanced lead compound 2-(1 Hydroxyethyl) imidazole 11 which exhibited low nanomolar inhibition of PaLpxC (functional IC$_{50}$ of 20 nM) and a minimal inhibitory concentration (MIC) of 4 μg/ml against P. aeruginosa (Figure 2). Further optimization and in vivo efficacy measurement are under consideration for this compound and will be described in a future publication. The lead compounds of both the series exhibited significant selectivity towards zinc metalloenzyme, LpxC. It was demonstrated that maintaining the zinc-chelation motif as it was in the fragments, engineering aliphatic linkers of appropriate length extending the fragments in the hydrophobic tunnel of LpxC and appending various hydrophobic groups at the para position of the benzyl successfully increased the potencies of compounds with retained ligand efficiencies.

Role of Aeropath Project in Fragment-Based Drug Discovery

An EU-funded project AEROPATH, coordinated by University of Dundee, was launched in November 2008 with the aim of identifying, characterising and exploiting novel drug targets from the Gram-negative bacterium, P. aeruginosa, by applying a multidisciplinary approach encompassing target validation, structural characterization, assay development and hit identification from small molecule libraries following a highthroughput or fragment-based screening campsains. Derivation of the structural models of the potential targets was one of the central aims of this project as the structural data allow druggability analysis of the active sites (Krasowski et al., 2011; Radoux et al., 2016) and support the curation of the structure-activity relationship of the identified ligands. Towards the end of this project, 102 targets were selected based on the available genome with preliminary annotation of P. aeruginosa strain PAO1 together with gene essentiality studies and other considerations such as feasibility of enzyme assays, chemogenomics information and an appropriate balance of novel uncharacterized proteins versus established targets for antibacterial drug design (Moynie et al., 2013). De novo structures of 39 of these targets were determined using X-ray crystallography and NMR. In addition, the structures of more than 60 complexes involving substrate, cofactor and inhibitors have been determined and published by the consortium. Crystal structures of eight targets including substrate, cofactor and inhibitors have been determined and published by the consortium. Crystal structures of eight targets including substrate, cofactor and inhibitors have been determined and published by the consortium.

Targeting Fatty Acid Biosynthesis Pathway

Fragment-Based Drug Discovery to Target FabG

The fatty acid synthesis type II (FAS II) system of bacteria has been identified as an attractive target for therapeutic interventions and several antibiotics targeting this pathway are

FIGURE 3 | An allosteric inhibitor (12) of PaFabG developed by FBDD with an IC$_{50}$ of 0.02 μM. The cosubstrate NADPH from PaFabG-NADPG complex (pdb id 4ag3) is mapped on the PaFabG-FG01 complex structure (pdb id 4bnu) determined by X-ray crystallography (Čukier et al., 2013). The inhibitor binds at the dimer-dimer interface of PaFabG. Binding of the inhibitor results in disturbance of the binding site of NADPH.
known, such as triclosan, isoniazid and thiolactomycin (Campbell and Cronan, 2001; Zhang et al., 2004; Heath and Rock, 2006; Parsons and Rock, 2011; Pan et al., 2012). FabG is a NADPH-dependent 3-oxoacyl-acyl carrier protein (ACP) reductase that plays a key role in the FAS II system of pathogenic microorganisms and has been identified as an attractive drug target. It catalyses the reduction of 3-oxoacyl-ACP to 3-D-hydroxyacyl-ACP intermediates during the elongation cycle of fatty acid biosynthesis (Rock and Jackowski, 2002; Goodman and McFadden, 2008; Chan and Vogel, 2010). FabG qualifies as a promising drug target due to its essentiality, high conservation across bacteria and presence of only a single isoform in most of the bacterial species (Zhang et al., 2004). Inhibitors of P. aeruginosa FabG (PaFabG) identified include largely natural product extracts that pose significant drug development challenges and hence none of them have reached the clinic (Zhang and Rock, 2004; Tasdemir et al., 2006; Wickramasinghe et al., 2006; Sohn et al., 2008; Zhang et al., 2008). As part of the AEROPATH project, Cyprian D. Cukier and coworkers have established the essentiality of fabG gene in P. aeruginosa using gene knockout procedure and following a FBDD approach they then developed a series of novel PaFabG inhibitors with IC50 values in nanomolar to low micromolar range and ligand efficiencies in the range of 0.37–0.53 (Cukier et al., 2013). Although the compounds show no phenotypic response in the Gram-negative P. aeruginosa either due to poor penetration of the compounds through the Gram-negative cell wall or to rapid efflux of the compounds, the diverse chemotypes of these inhibitors presents a number of options for optimization to increase intracellular concentrations. Structural investigation of 16 PaFabG-inhibitor complexes by X-ray crystallography in this study reveals that inhibitors bind at a novel allosteric site (cryptic binding site) located at the dimer-dimer interfaces of PaFabG (Figure 3) and this binding induces the conformational changes that propagate to the active site and results in the disturbance of the catalytic triads (residues S141, Y154, and K158) with loss in the binding affinity of cosubstrate NADH, thus inhibiting the enzyme. Kinetic analysis of inhibition suggested a noncompetitive mode of inhibition with respect to NADH.

**ANTI-VIRULENCE STRATEGIES AGAINST P. AERUGINOSA**

Antibiotic development to treat P. aeruginosa infections is undergoing a crisis due to the rapid evolution and spread of resistance in bacteria against the current antibiotics. Interfering with bacterial virulence network including virulence factors (proteases, elastase, endotoxins, and polycyokin), lipopolysaccharides, flagella, extracellular polysaccharides, and type II, III, IV and VI secretion system, instead of targeting their viability (growth and survival), to combat P. aeruginosa infections offers tantalizing prospects of novel antimicrobials and this approach has gained momentum in recent years to overcome today’s crisis in antibacterial development (Papaioannou et al., 2013; Anantharajah et al., 2016; Gao et al., 2017; Boulant et al., 2018; Ranjbar et al., 2019). Moreover, this strategy will reduce the propensity to induce resistance as it removes the strong selection pressure imposed by bacteriostatic or bactericidal agents.

**Targetting Quorum-Sensing Systems to Develop “Second Generation” Antibiotics**

Inhibiting quorum-sensing systems (QSS) and the regulators that promote biofilm formation is one such novel strategy to attenuate P. aeruginosa virulence (O’Loughlin et al., 2013; Shao et al., 2020; Manos, 2021). Four Q5 pathways (pqs, iqs, las, rhl) have been identified in P. aeruginosa (Lee et al., 2013). Of these, pqs and las mediated QSS have been targeted using FBDD and this will be described in the following section of this review.

**Fragment-Based Drug Discovery on LasB**

LasB (or pseudolysin, Pseudomonas elastase B) is the most abundant extracellular collagenase protease secreted by P. aeruginosa with a hydrolysis activity against a broad spectrum of substrate proteins from the host, causing damage to host tissues, disruption of the host immune response and promoting inflammation associated with P. aeruginosa virulence and disease pathology (Wretlind and Pavlovskis, 1983; Saint-Criq et al., 2018; Galdino et al., 2019). Since LasB is extracellular the direct inhibitors are not required to cross the difficult-to-peneatrate P. aeruginosa cell membrane and the fact that the target belongs to a class of validated drug targets (metalloprotease), against which there are already clinically useful drugs, makes LasB an attractive antivirulence target for therapeutic intervention (Galdino et al., 2019). Synthesis of small-molecule inhibitors of P. aeruginosa LasB (PaLasB) had started more than 40 years ago and since then eighteen inhibitors have been developed (Everett and Davies, 2021). The FBDD approach to develop inhibitors against PaLasB started in 2012 by screening a library of 96 metal chelating fragments (CFL-1.1) (a library designed specifically with fragments which can coordinate with the metal ion in the active site of metalloproteins) against PaLasB and the initial hits were followed up by medicinal chemistry optimization program (Agrawal et al., 2008; Garner et al., 2012). This led to the development of a thiopyridone 13 (Garner et al., 2012) with an IC50 of 2.73 μM for PaLasB but was promiscuous with regard to other metalloproteases, and the tropolone 14 (Fullagar et al., 2013) exhibiting similar potency (IC50 of 1 μM for LasB) but had better selectivity over human metalloproteases, such as matrix metalloproteases (MMPs) and carbonic anhydrase II (Figure 4A). They were the first potent non-peptidic small molecule antagonists discovered (Cathcart et al., 2011) and the first targetted compounds exhibiting ant-swarming activity (Garner et al., 2012).

With the aim of expanding the chemical space of PaLasB inhibitors, a functional screening based on FRET-based in vitro assay (Nishino and Powers, 1980) was performed against PaLasB using 330 fragments (Maybridge Fragment Library) and a protease inhibitor-enriched library (Baell and Holloway, 2010) comprising of 1,192 low molecular weight compounds (Kany et al., 2018a). This study led to the development of a thiobenzamide (N-(3,4-dichlorophenyl)-2-sulfanylacetamide) 15, LasB inhibitor with thiol
warhead, with an IC₅₀ of 6.6 μM (Figure 4A). This was selective with regard to human MMPs. The X-ray structure of PaLasB-15 complex revealed that binding of 15 to LasB does not necessarily lead to closure of the binding site (Kany et al., 2018a), unlike that described for thermolysin-like proteases (Adekoya et al., 2015), enzymes with high structural similarity to LasB. Moreover, two molecules of 15 were observed in the structure (Figure 4B) and the binding of the second molecule was supposed to be supported by the binding of the first molecule. However, the Hill coefficient of 1 in the in vitro assay for 15 suggested that only one binding event was necessary for full inhibition of PaLasB. Nevertheless, this structure with two binding sites for 15 paved the way for the development of novel LasB inhibitors targeting the open conformation of the enzyme. Attempts to merge these two molecules into one N-benzylamide derivative did not provide the desired activity. Growing the non-zinc-chelating molecule of 15 in the PaLasB-15 complex led to the development of N-arylsuccinimide 16 with an IC₅₀ of 4 μM, which showed, 1) significant selectivity for bacterial LasB over human MMPs and three other off-targets and 2) no signs of cytotoxicity in human cell lines (Konstantinović et al., 2020). In a another subsequent study, the zinc-chelating molecule of 15 in the PaLasB-15 complex was modified by changing the zinc-chelating moiety leading to a hydroxamate 17 (Kany et al., 2018b) with an IC₅₀ of 17 μM with moderate cytotoxic effects towards mammalian cell lines. Since only one molecule of 17 was observed in the crystal structure of PaLasB-17 complex (Figure 4C), unlike that of 15 in PaLasB-15 complex, and 17 was less susceptible to oxidation in air, the authors preferred 17 over 15 for further exploration. Moreover, 17 could undergo the characteristic hinge-bending motion resulting in closure of LasB binding site unlike open conformation as observed in PaLasB-15 complex. Overall, given their modest activities, the authors suggest that the molecules such as 15, 16 and 17 should be considered as starting points for further chemistry rather than as potential drug development candidates which could pave the way for the rational development of selective protease inhibitors as potential new antibiotics.

Exploiting the alternative binding modes of 15 to guide efficient fragment growing resulted in a series of compounds with better activities (Kaya et al., 2021). Compound 18 thus developed had an IC₅₀ of 1.2 μM (Figure 4A) and maintains the selectivity as 15. PaLasB-18 complex structure was determined by x-ray crystallography. Here again, the binding of 18 to PaLasB leads to closure of the binding site. This structure provided a deeper understanding of the possible interactions in the surrounding unoccupied space and complemented with docking analysis it paved the way for further optimization. A focused, substrate-inspired structure-based optimization of 18 (substitution of methyl group at the para position on the aromatic
core of N-arylacetamide) resulted in compound 19 (Figure 4A) with fourteen-fold boost in activity (IC$_{50}$ 0.48 μM) compared to 15 (173).

In vivo efficacy of these compounds was investigated using an insect model, Galleria mellonella and PA14, a virulent strain of P. aeruginosa. Since Galleria mellonella and mice show similar virulence patterns when infected with mutant PA14 strains (PA14, virulent strain of P. aeruginosa) this insect is likely to be a good model system to perform in vivo studies (Jander et al., 2000). Administering the anti-LasB compound 15 thus generated by FBDD campaign has shown significant increase in the survival of Galleria mellonella larvae infected with PA14. For instance, injection of 2.5 nM of 15 in the P14 infected larvae increased the survival of the larve from 43 to 73% after 65 h (Kany et al., 2018a). Compound 19 with better IC$_{50}$ showed enhanced in vivo efficacy compared to 15, thereby accelerating the translational path (Kaya et al., 2021). Antivirulent agents targeting quorum sensing of P. aeruginosa have previously been shown to enhance the survival of Galleria mellonella larvae infected with PA14 (Lu et al., 2014; Thomann et al., 2016). These compounds attain this efficacy by inhibiting the swarming and biofilm formation rather than being bacteriocidal. For instance, presence of compound 17 reduces the formation of biofilm and release of extracellular DNA by P. aeruginosa. The advantage of such inhibitors is that they are capable of disrupting several important bacterial resistance mechanisms and hence open novel avenues to combat multidrug resistant strains of P. aeruginosa.

**Fragment-Based Drug Discovery on PqsD**

PqsD is a key enzyme in the biosynthesis of signal molecules 2-heptyl-4-hydroxyquinoline (HHQ) and Pseudomonas quinolone signal (PQS) that are involved in the regulation of virulence factor (pyocyanine, elastase B, lectin A, rhamnolipids, and hydrogen cyanide) production and biofilm formation in P. aeruginosa (Van Delden and Iglewski, 1998; Diggle et al., 2003; Déziel et al., 2005; Yang et al., 2009). It has been shown that a mutant P. aeruginosa having a transposon insertion in the pqsA gene (deficient in HHQ and PQS production) forms less biofilm than the wild type (Gallagher et al., 2002; Müsken et al., 2010). Using a ligand-based approach the first class of PqsD inhibitors were identified which repressed HHQ and PQS production and biofilm formation in P. aeruginosa, validating PqsD as an attractive anti-biofilm target for the development of novel anti-infectives (Storz et al., 2012). Elisabeth Weidel and co-workers performed an SPR-based fragment screening against P. aeruginosa PqsD (PaPqsD) using a library of 500 fragments (Maybridge) with high structural diversity covering large chemical space in order to identify new scaffold for drug discovery (Koch, 2017). This screen resulted in identification of three fragments exhibiting a moderate inhibition of PaPqsD (Table 3). Two compounds showed strong inhibition of PaPqsD and hence these may be the starting point for future investigations.

**Targeting Disulfide Mediated Protein Folding**

**Fragment-Based Drug Discovery on DsbA1**

Oxidative protein folding is essential for assembly and function of many secreted and membrane proteins, and

| Fragment | Structure | Inhibition of PaPqsD |
|----------|-----------|---------------------|
| 20       | ![Fragment 20](image) | >99%                |
| 21       | ![Fragment 21](image) | 58%                 |
| 22       | ![Fragment 22](image) | 80%                 |

**TABLE 3** Fragment-like inhibitors of PaPqsD obtained by a FBDD campaign with two fragments showing strong inhibition (85%) of PaPqsD.

**FIGURE 5** Binding site of fragment 23 (obtained by a FBDD campaign) to the non-catalytic allosteric surface site of PaDsbA1 as revealed by the PaDsbA1-23 complex (pdb id 5dch) obtained using X-ray crystallography (Mohanty et al., 2017).

**Arif et al. FBDD Targeting Pseudomonas aeruginosa Infections**

Frontiers in Molecular Biosciences | www.frontiersin.org March 2022 | Volume 9 | Article 857000
DSB (disulfide bond) proteins that catalyze the disulfide bond formation are essential for virulence of many Gram-negative bacteria and hence these proteins are targets for novel antibacterial drugs (Heras et al., 2009). DsbA, an enzyme of disulfide oxidoreductase family, and its membrane-bound partner DsbB together catalyze the oxidative folding of disulfide bond containing proteins, many of which are virulence factors including secreted toxins and cell surface components, such as adhesins and pili. DsbA1 in \textit{P. aeruginosa} (\textit{Pa}DsbA1) plays a pivotal role in the oxidative folding of virulence factors qualifying it as an attractive target for the development of new anti-virulence antimicrobials (Braun et al., 2001; Urban et al., 2001; Ha et al., 2003). In a FBDD approach, \textit{Pa}DsbA1 was screened against a library of 1,137 fragments (Bradley et al., 2013) using ligand-detected STD NMR, which identified small molecules that bind selectively to \textit{Pa}DsbA1 over \textit{E. coli} DsbA (EcDsbA) suggesting the feasibility of species-specific development of narrow-spectrum inhibitor of \textit{Pa}DsbA1 (Mohanty et al., 2017). Structural characterization of the complex of \textit{Pa}DsbA1 with fragment 23 (highest affinity fragment with $K_D$ of 0.9, ligand efficiency 0.27 and lipophilic ligand efficiency of 0.26) using both X-ray crystallography and HADDOCK model revealed that the fragment is positioned at an interface between the thioredoxin (TRX) and helical domains of \textit{Pa}DsbA1 on the non-catalytic face (Figure 5) of the enzyme. Unfortunately, fragment 1 had no inhibitory effect on the enzymatic activity of \textit{Pa}DsbA1 as shown in an in vitro model-peptide folding assay. Nevertheless, these findings represent a starting point for the development of high affinity allosteric inhibitors of \textit{Pa}DsbA1.

**Fragment-Based Drug Discovery on GRX:**

**Development of Covalent Inhibitors of P. aeruginosa by Fragment-Based Drug Discovery**

Inspired by the need to develop novel classes of drug molecules targeting unconventional drug targets using a mechanism that can circumvent the efflux-mediated resistance mechanism, covalent inhibitors were sought. The present strategy involves combining a covalently reactive functional group with targeting moieties (of compounds)
selective for species-specific proteins from important biochemical pathways that might have been missed due to cross-reactivity issues to the host organism. Such atypical protein targets are less likely to contain resistance-conveying mutations. Moreover, if the targeted pathway is fundamentally essential to the bacterial metabolism then infectious colonies are less likely to undergo viable mutations. Such targets from *P. aeruginosa* are the glutaredoxins. Glutaredoxins are component of thiol-disulfide glutaredoxins systems of bacteria that favour reducing conditions for the correct disulfide bonding of the functional protein and therefore they are employed by bacteria to defend against oxidative stress imposed by host (Norambuena et al., 2012). Hence glutaredoxins are considered as potential drug targets. An NMR-led FBDD campaign targeted the *P. aeruginosa* glutaredoxin (PaGRX) (Khattari et al., 2020). This work involved: 1) generating PaGRX-specific fragment hits by screening 463 fragment molecules using independent STD NMR measurements, 2) NMR-based modeling of PaGRX, 3) NMR-guided docking of hits and 4) derivatising the fragment hit with a vinyl cysteine trap moiety (acylamide warhead with strong tendency to form alkylated cysteine adducts) to generate the chimeric lead (Figure 6). The authors show that mM to μM selectivity can be achieved for a few fragments against orthologous proteins and the promising fragment can be optimised to enhance the selectivity by choosing an appropriate warhead. For instance, fragment 24 which binds to PaGRX with moderate specificity (Kd = 0.51 ± 0.37 and LE = 0.32), when coupled with acrylic acid warhead showed enhanced specificity towards the enzyme. This can be further developed to result in to thiol-transferase inhibitory drug candidate against *P. aeruginosa*.

**Targetting Effector Proteins of Type III Secretion System of *P. aeruginosa***

Type III secretion system (T3SS) plays a pivotal role in the virulence and development of antimicrobial resistance of *P. aeruginosa* by providing a diverse range of virulence factors. Readers of this review are referred to a recent review by Gertrudis Horna and Joaquim Ruiz (Horna and Ruiz, 2021b) for more details on the T3SS machinery of *P. aeruginosa*. T3SS is aimed to inject the effectors in host-cells, subverting cellular machinery and neutralising the host immune responses, thereby enhancing bacterial survival rates in a hostile environment within the macrophages. Hence, T3SS impairment opens up opportunities for developing antimicrobial agents to combat *P. aeruginosa* infections avoiding antimicrobial pressure on this and other microorganisms (Aburto-Rodríguez et al., 2021; Horna and

---

**FIGURE 7** | Criteria for selecting protein targets from *P. aeruginosa* to be studied using FBDD. Different weights were given to the different criteria according to their impact on target selection.
Ruiz, 2021a). Until now six effector proteins (ExoS, ExoT, ExoU, ExoY, PemA, PemB) have been reported to be encoded by the T3SS of *P. aeruginosa* (Hueck, 1998; Barbieri and Sun, 2004; Hauser, 2009; Burstein et al., 2015), while four new putative effectors have recently been proposed (Zelikman et al., 2020). Of these, ExoU, ExoS, ExoT and ExoY have been studied most extensively. Drug development other than FBDD campaign have produced small molecule inhibitors of ExoU (Lee et al., 2007; Foulkes et al., 2021), ExoS (Arnoldo et al., 2008) and an inhibitor leading to decrease in secretion of ExoT and ExoY (Sheremet et al., 2018). Most of the components are yet to be investigated for inhibitor development. Thus, there is scope for the development of small molecule inhibitors using FBDD targeting these and other unexplored effectors which could interfere with these effectors and enhance the internalisation of *P. aeruginosa* infections by macrophages.

**FIGURE 8 | FBDD against PaDapD. (A)** Binding site and fragment hotspot maps of PaDapD. The yellow region in the zoomed view represents the hydrophobic map while hydrogen-bond acceptor and hydrogen-bond donors are represented in red and blue, respectively. **(B)** ligands from various PaDapD-ligand complexes mapped on the structure of PaDapD. 25 binds at two different sites in the protomer-protomer interfaces of PaDapD. 25 at site A overlaps with the binding site of the substrate analog L2AP, while that at site B overlaps with the binding site of the cofactor SCA.

**FRAGMENT-BASED DRUG DISCOVERY AGAINST P. AERUGINOSA AT UNIVERSITY OF CAMBRIDGE**

In 2017, United Kingdom Cystic Fibrosis Trust announced a £10 million research partnership with the University of Cambridge to create the first United Kingdom Cystic Fibrosis Innovation Hub with an aim to develop life-changing new treatments for people with CF. The CF innovation hub is hosted by Department of Medicine and led by Professor Andres Floto. It harnesses a multidisciplinary approach with the aim of delivering new treatments for bacterial infections, chronic inflammation, and lung repair for patients with CF. The Arif and Blundell contribution to the United Kingdom Cystic Fibrosis Innovation Hub at the University of Cambridge is to develop new antibiotics against *P. aeruginosa* and *M. abscessus*. We use computational approaches to understand the gene products that
might be appropriate targets by modelling three-dimensional structures (Sali and Blundell, 1993), often of multiprotein assemblies, understanding the impacts of mutations (Pires et al., 2014; Pandurangan et al., 2017; Pandurangan and Blundell, 2020) and assessing the essentiality of the gene. We then use structure-guided fragment-based drug discovery, pioneered in Cambridge in Astex in 1999 (see review Blundell et al., 2002), to develop candidate molecules in our biochemistry and structural biology laboratories and in collaboration with medicinal chemists in the group founded by Professor Chris Abell in Cambridge. Arif and Blundell also work very closely with Prof. Andres Floto, Research Director of the Cambridge Centre for Lung Infection at Papworth Hospital, Cambridge. His team carries out in vivo biological assays to test for the effects of elaborated compounds (inhibitors) on the cell system.

Funded as part of the Cystic Fibrosis Hub we began to focus on targets from *P. aeruginosa* and *M. abscessus*. A number of considerations for target selection such as gene essentiality in vitro and in vivo (Liberati et al., 2006; Skurnik et al., 2013; Lee et al., 2015; Turner et al., 2015; Basta et al., 2017), for example having little or no sequence identity to human or gut microbiome counterparts, the availability of apo and liganded crystal structures that suggest good ligandability, cellular localization of the protein, feasibility of functional/enzymatic assays for the target, were applied to prepare a list of targets from *P. aeruginosa* with ranking based on associated target selection scores (Figure 7).

**Targeting DapD: An Essential Protein of the Lysine Biosynthesis Pathway**

Bacterial genetic studies have suggested that the lysine biosynthesis pathway is essential and offers several potent antibacterial enzyme targets that could be explored (Cox et al., 2000; Hutton et al., 2007; Gillner et al., 2013). DapD (2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase), a product of an essential gene involved in the lysine biosynthesis pathway, was selected as an initial target. *P. aeruginosa* DapD (*Pa* DapD) was ranked at the very top in the list of potential targets. The lack of human homolog of DapD and maximum identity of 36% to a homolog from human gut microbiome qualifies it for a potential target as this would likely avoid any cross reactivity of the developed inhibitors. DapD catalyses the conversion of cyclic tetrahydrodipicolinate (THDP) into the acyclic *N*-succinyl-2,6-oxopimelate using succinyl-CoA (SCA) as cofactor. Detailed structural analyses of the available complexes with substrate and cofactors suggest that a long narrow crevice is formed at each interface of the *Pa*DapD trimer where the reactants bind (Schnell et al., 2012). Analysis using the HOTSPOT server (50) strongly suggests that this binding site is suitable for the binding of fragments (Figure 8A). We speculated that elaborated small molecules that bind to these sites will potentially block the binding of substrate/cofactor and will eventually inactivate the enzyme.

![Figure 9](image-url)
An initial fragment screening employing the differential scanning fluorimetry (DSF) using our in-house library of 960 fragments resulted in 10 promising compounds that could bind to the protein, as all led to a positive shift in the thermal melt temperature of the protein. We then produced crystal structures of apo-PaDapD and binary complexes of PaDapD with fragment 25, the cofactor succinyl CoA (SCA); with the substrate analogue L-2-amino pimelic acid (L2AP). SCA binds in the narrow pocket at the interface formed between the N-terminal, middle and C-terminal part of the neighbouring protomers. L2AP binds at the N-terminal region of the pocket near succinyl β-mercaptoethylamine moiety of SCA (Figure 8B). 25 binds at a location (25-A) coinciding with the L2AP binding site. At higher concentrations of 25 a second binding site (25-B) is observed that overlaps with part of the SCA binding site (Figure 8B). The structure of PaDapD-L2AP complex differs from the apo-PaDapD and PaDapD-SCA complexes where it was helical, is extended and covers the active site resulting in a cage like structure of the binding pocket (Figure 9). Another large change is observed in the C-terminal tail region, which, unlike in the apo-PaDapD and PaDapD-SCA complexes where it was helical, is extended and covers the active site resulting in a cage like structure of the binding pocket (Figure 9). A comparison of the binary complexes of L2AP and 25 demonstrates a similarity in the conformational changes observed upon their binding to the active site (Figure 9), which might guide the design of inhibitors against the enzyme.

Proximity of 25 and substrate analog L2AP suggests a structure-guided substrate-inspired growing of the fragment (Figure 10A) in order to potentiate it for binding to PaDapD. Another strategy could be to merge the fragments on the basis of the two binding sites observed in the PaDapD-25 complex to develop compound 29. The binding and inhibition of these compounds to PaDapD needs to be investigated.

*FIGURE 10* | Fragment growing and fragment merging strategies based on the structure of PaDapD-25 and PaDapD-L2AP complexes. (A) substrate-inspired growing of an 25-analog 26 based on the structures of PaDapD-26 and PaDapD-L2AP complexes resulting in compound 27 and 28. The feasibility of the fragment growing is enhanced when performed on 26. (B) Merging of 25 at sites A and B of PaDapD employing suitable linker based on the structure of PaDapD-25 complex to develop compound 29. The binding and inhibition of these compounds to PaDapD needs to be investigated.

*FIGURE 11* | Tetrameric structure of PaKdsA and binding sites/hotspots identified by HOTSPOT. Two sites, site A and B have been identified to which fragments are predicted to bind.
of Professor Chris Abell. The plan remains that the resulting compounds (compounds 27, 28 and 29) will then be tested for the binding to PaDapD using DSF, ITC and SPR.

**Targeting KdsA: An Enzyme in Lipopolysaccharide Biosynthesis Pathway**

As LPS has an important role in the structural integrity of the bacterium and its defence against the host, the enzymes of the LPS biosynthesis pathway are attractive drug targets. Four of them KdsA, KdsB, LpxC and WaaG were selected for homology modeling with the aim of developing inhibitors against them. Subsequently, the essentiality of KdsA for the survival and virulence of the *P. aeruginosa* was validated experimentally (Perumal et al., 2011).

KdsA, a 3-deoxy-D-manno-octulosonate 8-phosphate (KDO8P) synthase, catalyses the condensation reaction between D-arabinose 5-phosphate (A5P) and phosphoenolpyruvate (PEP). This enzymatic reaction plays an essential role in the synthesis and assembly process of lipopolysaccharides of most Gram-negative bacteria and is therefore an attractive target for the design of novel antibacterial drugs. The crystal structures of *E. coli* KdsA as binary complexes with the substrate, PEP, and with a mechanism-based inhibitor (Ki = 0.4 μM), gave insight about its mechanism of action and inhibition. Interestingly, KdsA belongs to a family of PEP-utilizing enzymes, two of which, UDPGlcNAc enolpyruvoyl transferase (MurZ) and 5-enolpyruvoylshikimate-3-phosphate synthase (EPSPS), are targeted by the antibiotic Fosfomycin and by the herbicide glyphosate, respectively. The crystal structure of *P. aeruginosa* KdsA (PaKdsA) in its binary complex with phosphoenolpyruvate (PEP) was reported in the year 2013 (Nelson et al., 2013). PaKdsA is a tetrameric enzyme and the binding site/hotspot of the *P. aeruginosa* KdsA was probed by generating fragment hotspot maps using the HOTSPOT program (50), which suggested the presence of promising pocket for targeting new therapeutics (Figure 11).

A fragment library of 480 non-redundant fragments was used for screening against PaKdsA employing DSF. 56 fragments showed negative shift in melting temperature while 14 fragments showed positive delta Tm shift. Unfortunately, none of them showed any binding to PaKdsA as determined using ITC and X-ray crystallography.

The protein was also used to produce crystals of apo protein for a crystal-based fragment screening, and in complex with the substrates, PEP and A5P, in order to locate the active site which could be used for a virtual screening campaign. The attempt with PEP resulted in PaKdsA-PEP complex and in the presence of A5P resulted in PaKdsA-A5P complex. When the two substrates were mixed and used for cocrystallization, a product (KDO8P) bound crystal, PaKdsA-KDO8P, was obtained. PEP binds deep in the binding pocket and A5P binds above PEP in a more solvent exposed location. KDO8P in its complex with PaKdsA spans the location of both PEP and A5P.

A high-throughput crystal-based fragment screening against PaKdsA was carried out at the XChem facility of Diamond Light Source (Figure 12A) using a total of 886 crystals, 42 for solvent characterisation and 844 for soaking fragments from three different fragment libraries, namely, DSI poised (Enamine) (647 fragments), EubOpen (109 fragments) and Spotfinder (88 fragments). 17 hits were obtained after this screening,
most of the fragments were bound at the sites generated by the crystal lattice while three fragments (30, 31 and 32) were bound near the active site of the enzyme (Figure 12B). The fragments binding near the active site could be starting points for hit-to-lead compound development against PaKdsA.

CONCLUSION

Our review of structure-guided fragment-based drug discovery to target *P. aeruginosa* infections demonstrates its great potential in the design of new medicines to combat infections in the lungs of cystic fibrosis patients. However, although *P. aeruginosa* is a common strict aerobic bacterium that can cause disease in plants and animals, including humans, research towards the development of molecules to target it, using fragment-based approaches, remains at an early stage. Nevertheless, as our review demonstrates, the studies are encouraging, although small in number. In the future, further investment will be required in taking leads though the clinic and this is as always a challenge for genetic diseases, which affect a small percentage of the population, even those that are relatively common in wealthy Western nations of North America and Western Europe. The challenge is exacerbated by the fact that this ubiquitous multidrug-resistant pathogen, *P. aeruginosa*, exhibits advanced antibiotic resistance mechanisms. We remain grateful to organisations such as the Cystic Fibrosis Trust that are giving generous support to research groups such as ours in moving new candidates into the clinic.

AUTHOR CONTRIBUTIONS

SA contributed to the conception, writing, and generation of graphical figures in this work. RF and TB contributed to the writing of the article and approved the submitted version.

FUNDING

TLB, RAF and SMA thank the Cystic Fibrosis Trust for funding support (RG70975) and for support through the Cystic Fibrosis Trust Innovation Hub (RG92393).

ACKNOWLEDGMENTS

TB, RF and SA thank the Cystic Fibrosis Trust for funding support (PHZJ_395, RG 70975) and for support through the Cystic Fibrosis Trust Innovation Hub (PHZJ_585, RG92393). SA and TB thank the editors for the invitation to participate in this research topic “Integration of Structural Biology Data in Lead Drug Discovery and Optimization”. SA thanks Prof. Anna K. H. Hirsch for kindly providing the coordinates of the unreleased pdb 7oc7.

REFERENCES

Aburto-Rodriguez, N. A., Muñoz-Cázares, N., Castro-Torres, V. A., González-Pedrajo, B., Díaz-Guerrero, M., García-Contreras, R., et al. (2021). Anti-pathogenic Properties of the Combination of a T3ss Inhibitory Halogenated Pyrrolidone with C-30 Furanone. *Molecules* 26, 7635. doi:10.3390/molecules26247635

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., et al. (2010). PHENIX: A Comprehensive Python-Based System for Macromolecular Structure Solution. *Acta Crystallogr. D Biol. Cryst. 66*, 213–221. doi:10.1107/S0907444909052925

Adekoya, O. A., Sẹlẹ, S., Wuxier, Y., Bilò, I., Marques, S. M., Santos, M. A., et al. (2015). Inhibition of Pseudolysin and Thermolysin by Hydroxamate-Based MMP Inhibitors. *Eur. J. Med. Chem. 89*, 340–348. doi:10.1016/j.ejmech.2014.10.009

Agrawal, A., Johnson, S. L., Jacobsen, J. A., Miller, M. T., Chen, L-H., and Hirsch for kindly providing the coordinates of the unreleased lead compound development against *P. aeruginosa* is a common strict aerobic bacterium that can cause disease in plants and animals, including humans, research towards the development of molecules to target it, using fragment-based approaches, remains at an early stage. Nevertheless, as our review demonstrates, the studies are encouraging, although small in number. In the future, further investment will be required in taking leads through the clinic and this is as always a challenge for genetic diseases, which affect a small percentage of the population, even those that are relatively common in wealthy Western nations of North America and Western Europe. The challenge is exacerbated by the fact that this ubiquitous multidrug-resistant pathogen, *P. aeruginosa*, exhibits advanced antibiotic resistance mechanisms. We remain grateful to organisations such as the Cystic Fibrosis Trust that are giving generous support to research groups such as ours in moving new candidates into the clinic.

AUTHOR CONTRIBUTIONS

SA contributed to the conception, writing, and generation of graphical figures in this work. RF and TB contributed to the writing of the article and approved the submitted version.

FUNDING

TLB, RAF and SMA thank the Cystic Fibrosis Trust for funding support (RG70975) and for support through the Cystic Fibrosis Trust Innovation Hub (RG92393).

ACKNOWLEDGMENTS

TB, RF and SA thank the Cystic Fibrosis Trust for funding support (PHZJ_395, RG 70975) and for support through the Cystic Fibrosis Trust Innovation Hub (PHZJ_585, RG92393). SA and TB thank the editors for the invitation to participate in this research topic “Integration of Structural Biology Data in Lead Drug Discovery and Optimization”. SA thanks Prof. Anna K. H. Hirsch for kindly providing the coordinates of the unreleased pdb 7oc7.

REFERENCES

Aburto-Rodriguez, N. A., Muñoz-Cázares, N., Castro-Torres, V. A., González-Pedrajo, B., Díaz-Guerrero, M., García-Contreras, R., et al. (2021). Anti-pathogenic Properties of the Combination of a T3ss Inhibitory Halogenated Pyrrolidone with C-30 Furanone. *Molecules* 26, 7635. doi:10.3390/molecules26247635

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., et al. (2010). PHENIX: A Comprehensive Python-Based System for Macromolecular Structure Solution. *Acta Crystallogr. D Biol. Cryst. 66*, 213–221. doi:10.1107/S0907444909052925

Adekoya, O. A., Sẹlẹ, S., Wuxier, Y., Bilò, I., Marques, S. M., Santos, M. A., et al. (2015). Inhibition of Pseudolysin and Thermolysin by Hydroxamate-Based MMP Inhibitors. *Eur. J. Med. Chem. 89*, 340–348. doi:10.1016/j.ejmech.2014.10.009

Agrawal, A., Johnson, S. L., Jacobsen, J. A., Miller, M. T., Chen, L-H., and Hirsch for kindly providing the coordinates of the unreleased lead compound development against *P. aeruginosa* is a common strict aerobic bacterium that can cause disease in plants and animals, including humans, research towards the development of molecules to target it, using fragment-based approaches, remains at an early stage. Nevertheless, as our review demonstrates, the studies are encouraging, although small in number. In the future, further investment will be required in taking leads through the clinic and this is as always a challenge for genetic diseases, which affect a small percentage of the population, even those that are relatively common in wealthy Western nations of North America and Western Europe. The challenge is exacerbated by the fact that this ubiquitous multidrug-resistant pathogen, *P. aeruginosa*, exhibits advanced antibiotic resistance mechanisms. We remain grateful to organisations such as the Cystic Fibrosis Trust that are giving generous support to research groups such as ours in moving new candidates into the clinic.

AUTHOR CONTRIBUTIONS

SA contributed to the conception, writing, and generation of graphical figures in this work. RF and TB contributed to the writing of the article and approved the submitted version.

FUNDING

TLB, RAF and SMA thank the Cystic Fibrosis Trust for funding support (RG70975) and for support through the Cystic Fibrosis Trust Innovation Hub (RG92393).

ACKNOWLEDGMENTS

TB, RF and SA thank the Cystic Fibrosis Trust for funding support (PHZJ_395, RG 70975) and for support through the Cystic Fibrosis Trust Innovation Hub (PHZJ_585, RG92393). SA and TB thank the editors for the invitation to participate in this research topic “Integration of Structural Biology Data in Lead Drug Discovery and Optimization”. SA thanks Prof. Anna K. H. Hirsch for kindly providing the coordinates of the unreleased pdb 7oc7.
Eşkanaz, A. E. (2021). Asacimib in Chronic Myeloid Leukemia: many Questions Still Remain to Be Answered. Blood Cancer J. 11, 10–11. doi:10.1038/s41408-021-00475-7

Esnar, W., Webb, B., Marti-Renom, M. A., Madhusudhan, M. S., Erman, D., Shen, M. Y., et al. (2006). Comparative Protein Structure Modeling Using Modeller. Curr. Protoc. Bioinformatics 15, 1–30. doi:10.1002/0471250953.ibt05615

Everett, M. J., and Davies, D. T. (2021). Pseudomonas aeruginosa Elastase (LasB) as a Therapeutic Target. Drug Discov. Today 26, 2108–2123. doi:10.1016/j.drudis.2021.02.026

Evers, B., Jastrzebski, K., Heijmans, J. P. M., Grernrum, W., Beijersbergen, R. L., Arif et al. FBDD Targeting Flume, P. A., O. Fullagar, J. L., Garner, A. L., Struss, A. K., Day, J. A., Martin, D. P., Yu, J., et al. Foulkes, D. M., McLean, K., Zheng, Y., Sarsby, J., Haneef, A. S., Fernig, D. G., et al. Gillner, D. M., Becker, D. P., and Holz, R. C. (2013). Lysine Biosynthesis in Ha, U.-H., Wang, Y., and Jin, S. (2003). DsbA of Hauduk, P. J., Olejniczak, E. T., and Fesik, S. W. (1997). One-dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds that Bind to Macromolecules. J. Am. Chem. Soc. 119, 12257–12261. doi:10.1021/ja971962G Halgren, T. A. (2009). Identifying and Characterizing Binding Sites and Assessing Drugability. J. Chem. Inf. Model. 49, 377–389. doi:10.1021/ci080324m

Hauser, A. R. (2009). The Type III Secretion System of Pseudomonas aeruginosa: Infection by Injection. Nat. Rev. Microbiol. 7, 654–665. doi:10.1038/nrmicro2199

Heath, R. J., and Rock, C. O. (2006). Fatty Acid Biosynthesis as a Target for Novel Antibacterials. Curr. Opin. Investig. Drugs 5, 146–153.

Heidrich, J., Spert, L. E., and Boeckler, F. M. (2019). Embracing the Diversity of Halogen Bonding Motifs in Fragment-Based Drug Discovery-Construction of a Diversity-Optimized Halogen-Enriched Fragment Library. Front. Chem. 7. doi:10.3389/fchem.2019.00089

Held, D., and Kila, P. (2021). Size-exclusion Chromatography as a Useful Tool for the Assessment of Polymer Quality and Determination of Macromolecular Properties. Chem. Teach. Int. 3, 77–103. doi:10.1515/citi-2020-0024

Heras, B., Shouldice, S. R., Totsika, M., Scanlon, M. J., Scem bri, M. A., and Martin, J. L. (2009). DSB Proteins and Bacterial Pathogenicity. Nat. Rev. Microbiol. 7, 215–225. doi:10.1038/nrmicro2087

Hoffer, L., Voitovich, Y. V., Raux, B., Carrasco, K., Muller, C., Fedorov, A. Y., et al. (2016). Integrated Strategy for Lead Optimization Based on Fragment Growing: The Diversity-Orientation-Target-Focused-Synthesis Approach. J. Med. Chem. 61, 5719–5732. doi:10.1021/acsmedchemlett.6b00653

Horna, G., and Ruiz, J. (2021a). Type 3 Secretion System as an Anti-pseudomonal Target. Micro. Pathogenesis 155, 104907. doi:10.1016/j.micpath.2021.104907

Hornea, S., and Sauer, M. G. (2015). Molecular Cloning Using Polymerease Chain Reaction, an Educational Guide for Cellular Engineering. J. Biol. Eng. 9, 2. doi:10.1186/1756-1141-9-2

Huang, B., and Schroeder, M. (2006). LIGSITEEcsc: Predicting Ligand Binding Sites Using the Connolly Surface and Degree of Conservation. BMC Struct. Biol. 6, 11–19. doi:10.1186/1472-6807-6-19

Hubbard, R. K., Davis, B., Chen, L., and Drysdale, M. (2007). The SEQs Approach: Integrating Fragments into Drug Discovery. Curr. Opin. Chem. Biol. 11, 1568–1581. doi:10.2174/1389203720666190207100415

Hubbard, R. B., and Murray, J. B. (2011). Experiences in Fragment-Based Lead Discovery. 1st ed. Elsevier, 509–531. doi:10.1016/B978-0-12-381274-2.00020-0

Hueck, C. J. (1998). Type III Protein Secretion Systems in Bacterial Pathogens of Animals and Plants. Microbiol. Mol. Biol. Rev. 62, 379–433. doi:10.1128/mmbr.62.2.379-433.1998

Hutton, C. A., Perugini, M. A., and Gerrard, J. A. (2007). Inhibition of Lysine Biosynthesis: An Evolving Antibiotic Strategy. Mol. Biosyst. 3, 458–465. doi:10.1039/b705624a

Ibrahim, D., Jabbour, J.-F., and Kanji, S. S. (2020). Current Choices of Antibiotic Treatment for Pseudomonas aeruginosa Infections. Curr. Opin. Infect. Dis. 33, 464–473. doi:10.1097/QO.0000000000000677

Irwin, J. J., and Shoichet, B. K. (2005). ZINC – A Free Database of Commericially Availble Compounds for Virtual Screening. J. Chem. Inf. Model. 45, 177–182. doi:10.1021/ci049714+

Jackman, J. E., Fierke, C. A., Tumey, L. N., Pirrong, M., Uchiyama, T., Sahr, S. H., et al. (2000). Antibacterial Agents that Target Lipid A Biosynthesis in Gram-Negative Bacteria. J. Biol. Chem. 275, 11002–11009. doi:10.23755/jbc.s275-11.11002

Jander, G., Rahme, L. G., and Ausubel, F. M. (2000). Positive Correlation between Virulence of Pseudomonas aeruginosa Mutants in Mice and Insects. J. Bacteriol. 182, 3843–3845. doi:10.1128/JB.182.13.3843-3845.2000

Jenkins, R. J., and Dotson, G. D. (2012). Dual Targeting Antibacterial Peptide Inhibitor of Early Lipid A Biosynthesis. ACS Chem. Biol. 7, 1170–1177. doi:10.1021/cb300094a

Jenkins, R. J., Heslip, K. A., Meagher, L. J., Stuckey, J. A., and Dotson, G. D. (2014). Structural Basis for the Recognition of Peptide RJPXDS by Acyltransferases in Lipid A Biosynthesis. J. Biol. Chem. 209, 15527–15535. doi:10.23755/jbc.m2014.564278

Jérabek-Willemsen, M., André, T., Wanner, R., Roth, H. M., Duhrl, S., Basse, P., et al. (2014). MicroScope Thermophoresis: Interaction Analysis and beyond. J. Mol. Struct. 1077, 101–113. doi:10.1016/j.molstruc.2014.03.009

Joo, S. H. (2015). Lipid A as a Drug Target and Therapeutic Molecule. Biomolecules Ther. 23, 510–516. doi:10.4062/biomolther.2015.117

Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly Accurate Protein Structure Prediction with AlphaFold. Nature 596, 583–589. doi:10.1038/s41586-021-03819-2

Kalvin, D. V., and Holl, R. (2017). LpCX: An Inhibitor of a Patent Review (2010-2016). Expert Opin. Ther. Patents 27, 1227–1250. doi:10.1080/13543776.2017.1362082

Kany, A. M., Sikandar, A., Haupenthal, J., Yahioua, S., Maurer, C. K., Proschak, E., et al. (2018a). Binding Mode Characterization and Early In Vivo Evaluation of Fragment-like Thiols as Inhibitors of the Virulence Factor LasB from Pseudomonas aeruginosa. ACS Infect. Dis. 4, 988–997. doi:10.1021/acsinfecdis.8b00010
